Antag Therapeutics is based on years of collaborative research from the University of Copenhagen with the focus on novel treatments for dietary-related metabolic diseases. The research teams of professors Mette Rosenkilde and Jens Juul Holst have discovered naturally occurring therapeutic peptides that are being investigated in several human studies.
Our mission is to develop first-in-class peptide drugs for the treatment of dietary-related metabolic diseases. Our drugs are based on a novel, effective, naturally occurring antagonist that modulates fat deposition and dysregulation of glycemia in diabetic patients.